Transgene Biotek Ltd
Incorporated in 1990, Transgene Biotek Limited is in the business of Research & Development of Pharmaceutical products. The registered office of the company is in Telangana.[1]
- Market Cap ₹ 54.0 Cr.
- Current Price ₹ 7.12
- High / Low ₹ 12.5 / 2.46
- Stock P/E
- Book Value ₹ 1.46
- Dividend Yield 0.00 %
- ROCE -20.0 %
- ROE -41.8 %
- Face Value ₹ 10.0
Pros
Cons
- Stock is trading at 4.86 times its book value
- Company has low interest coverage ratio.
- Promoter holding is low: 23.6%
- Company has a low return on equity of -43.5% over last 3 years.
- Company might be capitalizing the interest cost
- Debtor days have increased from 41.0 to 60.8 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Healthcare Industry: Miscellaneous
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
26.24 | 15.01 | 0.98 | 0.30 | 0.18 | 0.28 | 0.12 | 0.07 | 0.00 | 0.17 | 0.09 | 0.06 | 0.20 | |
25.12 | 15.83 | 2.81 | 1.90 | 1.32 | 2.84 | 2.22 | 0.75 | 0.87 | 0.70 | 0.55 | 0.68 | 0.78 | |
Operating Profit | 1.12 | -0.82 | -1.83 | -1.60 | -1.14 | -2.56 | -2.10 | -0.68 | -0.87 | -0.53 | -0.46 | -0.62 | -0.58 |
OPM % | 4.27% | -5.46% | -186.73% | -533.33% | -633.33% | -914.29% | -1,750.00% | -971.43% | -311.76% | -511.11% | -1,033.33% | -290.00% | |
17.07 | 0.00 | -114.37 | 0.01 | 0.17 | 0.66 | 7.37 | 2.04 | 0.18 | 0.27 | 0.21 | 0.18 | 0.16 | |
Interest | 0.62 | 0.20 | 0.00 | 0.36 | 0.07 | 0.43 | 1.03 | 0.26 | 0.38 | 0.27 | 0.23 | 0.62 | 0.14 |
Depreciation | 0.38 | 1.02 | 17.22 | 17.18 | 20.50 | 17.53 | 9.89 | 9.89 | 9.90 | 9.91 | 9.92 | 4.95 | 1.30 |
Profit before tax | 17.19 | -2.04 | -133.42 | -19.13 | -21.54 | -19.86 | -5.65 | -8.79 | -10.97 | -10.44 | -10.40 | -6.01 | -1.86 |
Tax % | 32.58% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -13.98% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | |
11.60 | -2.03 | -133.41 | -19.14 | -21.54 | -19.86 | -6.44 | -8.79 | -10.96 | -10.43 | -10.40 | -6.01 | -1.86 | |
EPS in Rs | 1.76 | -0.31 | -17.61 | -2.53 | -2.84 | -2.62 | -0.85 | -1.16 | -1.45 | -1.38 | -1.37 | -0.79 | -0.25 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | -42% |
5 Years: | -13% |
3 Years: | % |
TTM: | 33% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | 6% |
3 Years: | 13% |
TTM: | 74% |
Stock Price CAGR | |
---|---|
10 Years: | 4% |
5 Years: | 9% |
3 Years: | 14% |
1 Year: | 180% |
Return on Equity | |
---|---|
10 Years: | -14% |
5 Years: | -33% |
3 Years: | -44% |
Last Year: | -42% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 65.77 | 65.77 | 75.77 | 75.77 | 75.77 | 75.77 | 75.77 | 75.77 | 75.77 | 75.77 | 75.77 | 75.77 |
Reserves | 245.12 | 256.17 | 130.20 | 115.62 | 98.67 | -16.90 | -23.34 | -32.13 | -43.10 | -53.53 | -58.39 | -64.40 |
20.76 | 22.46 | 13.06 | 14.43 | 15.28 | 16.01 | 9.84 | 9.14 | 10.33 | 11.33 | 12.01 | 13.11 | |
34.06 | 24.22 | 139.32 | 137.95 | 123.27 | 123.18 | 124.28 | 123.77 | 123.75 | 123.31 | 117.71 | 117.87 | |
Total Liabilities | 365.71 | 368.62 | 358.35 | 343.77 | 312.99 | 198.06 | 186.55 | 176.55 | 166.75 | 156.88 | 147.10 | 142.35 |
106.82 | 197.80 | 180.58 | 163.40 | 140.95 | 61.16 | 50.97 | 41.10 | 31.20 | 21.32 | 11.40 | 6.45 | |
CWIP | 0.23 | 0.29 | 0.29 | 0.29 | 0.29 | 2.04 | 1.87 | 1.87 | 1.87 | 1.87 | 1.87 | 1.87 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.10 | 0.10 |
258.66 | 170.53 | 177.48 | 180.08 | 171.75 | 134.86 | 133.71 | 133.58 | 133.68 | 133.69 | 133.73 | 133.93 | |
Total Assets | 365.71 | 368.62 | 358.35 | 343.77 | 312.99 | 198.06 | 186.55 | 176.55 | 166.75 | 156.88 | 147.10 | 142.35 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
25.34 | 13.00 | -2.11 | 3.52 | 6.47 | 0.02 | -0.63 | -1.74 | 0.14 | 0.01 | 0.10 | 0.00 | |
-144.15 | -15.35 | 1.45 | -4.57 | -6.47 | 0.00 | 3.05 | 1.74 | 0.00 | -0.03 | -0.10 | -0.01 | |
82.72 | 2.41 | 0.60 | 1.03 | 0.00 | 0.00 | -2.37 | 0.00 | -0.20 | 0.00 | 0.00 | 0.00 | |
Net Cash Flow | -36.09 | 0.06 | -0.05 | -0.02 | 0.00 | 0.02 | 0.05 | 0.00 | -0.06 | -0.01 | 0.00 | -0.01 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 394.77 | 448.16 | 6,797.19 | 19,953.33 | 3,325.56 | 13.04 | 30.42 | 52.14 | 21.47 | 40.56 | 60.83 | |
Inventory Days | 12.92 | 6.40 | 106.46 | 365.00 | 365.00 | 1,460.00 | 121.67 | 156.43 | ||||
Days Payable | 442.19 | 437.74 | 25,975.83 | 5,018.75 | 3,528.33 | 13,870.00 | 1,460.00 | 1,199.29 | ||||
Cash Conversion Cycle | -34.51 | 16.82 | -19,072.18 | 19,953.33 | 3,325.56 | 13.04 | -4,623.33 | -3,111.19 | -1,316.86 | 40.56 | -982.02 | |
Working Capital Days | -39.09 | 51.07 | 648.06 | 1,399.17 | 2,108.89 | -1,864.11 | -21,717.50 | -36,239.29 | -14,514.12 | -5,231.67 | -8,638.33 | |
ROCE % | 6.42% | -0.53% | -6.48% | -8.83% | -10.86% | -14.69% | -10.97% | -17.91% | -22.11% | -26.56% | -32.31% | -20.01% |
Documents
Announcements
- COMPLIANCE CERTIFICATE AS PER CLAUSE 40(9) OF SEBI (LODR) REGULATIONS, 2015 FOR THE YEAR ENDED 31St MARCH 2024. 1d
- Statement Of Deviation & Variation 23 Apr
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 23 Apr
- Compliance Certificate Reg 7(3) 23 Apr
- Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A 23 Apr
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
-
Financial Year 2009
from bse
Business Expertise:[1]
Company is in production and oral formulation of different proteins using TrabiORAL technology
a) Oncology[2]
b) Auto Immunity[3]
c) Drug Delivery[4]
d) Biogenerics[5]